

# Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2019

<https://marketpublishers.com/r/S5A0AD0F600EN.html>

Date: April 2019

Pages: 85

Price: US\$ 3,500.00 (Single User License)

ID: S5A0AD0F600EN

## Abstracts

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2019

### SUMMARY

According to the recently published report 'Smoothened Homolog - Pipeline Review, H1 2019'; Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

The report 'Smoothened Homolog - Pipeline Review, H1 2019' outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules,

respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Immunology and Undisclosed which include indications Adenocarcinoma Of The Gastroesophageal Junction, Gorlin Syndrome (Basal Cell Nevus Syndrome/Nevoid Basal Cell Carcinoma Syndrome), Medulloblastoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Leukemias, Peritoneal Cancer, Prostate Cancer, Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Cirrhosis, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Graft Versus Host Disease (GVHD), Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Neuroendocrine Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Unspecified.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)

The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects

The report assesses Smoothened Homolog (Protein Gx or SMO) targeted

therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Smoothened Homolog (Protein Gx or SMO) - Overview

Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development

AlfaSigma SpA

F. Hoffmann-La Roche Ltd

Genentech Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

IMPACT Therapeutics Inc

Mayne Pharma Group Ltd

PellePharm Inc

Pfizer Inc

Sun Pharma Advanced Research Company Ltd

Smoothened Homolog (Protein Gx or SMO) - Drug Profiles

glasdegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSA-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GT-1708 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-5471 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patidegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize SMO for Colon Cancer and Medulloblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target SMO and HDAC for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize SMO for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Smoothed Homolog for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sonidegib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taladegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vismodegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZSP-1602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Smoothened Homolog (Protein Gx or SMO) - Dormant Products

Smoothened Homolog (Protein Gx or SMO) - Discontinued Products

Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones

Featured News & Press Releases

Apr 01, 2019: PellePharm initiates pivotal phase 3 clinical trial of Patidegib topical gel in patients with gorlin syndrome

Jan 30, 2019: Tolsura (suba-itraconazole) antifungal capsule now available in the United States

Dec 18, 2018: Mayne Pharma announces US commercial rights for Suba-itraconazole in BCCNS

Dec 12, 2018: Mayne pharma receives FDA approval of Tolsura (Suba-Itraconazole capsules) for the treatment of certain fungal infections

Nov 23, 2018: FDA approves Pfizer's Daurismo to treat acute myeloid leukaemia

Oct 15, 2018: Pellepharm presents updated data from two phase 2 studies demonstrating the potential of Patidegib topical gel to treat basal cell carcinomas in patients with gorlin syndrome and in patients with non-gorlin sporadic bccs

Oct 11, 2018: HedgePath Pharmaceuticals to present at the 2018 BioFlorida Annual Conference

Oct 09, 2018: HedgePath Pharmaceuticals pathway for filing SUBA BCCNS NDA clarified in Meeting with FDA

Aug 06, 2018: HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request

Jun 27, 2018: U.S. FDA Grants Priority Review for Pfizer's New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia

Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway

May 21, 2018: HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage

May 16, 2018: PellePharm to present topical Patidegib and skin cancer epidemiological data at the 7th International Investigative Dermatology Meeting

May 14, 2018: HedgePath Pharmaceuticals Announces Expanded Patent Coverage

May 02, 2018: Mayne Pharma Announces FDA Acceptance of New Drug Application for Its Antifungal Suba-Itraconazole Capsule

Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2019  
Number of Products under Development by Therapy Areas, H1 2019  
Number of Products under Development by Indications, H1 2019  
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019  
Number of Products under Development by Companies, H1 2019  
Products under Development by Companies, H1 2019  
Number of Products under Investigation by Universities/Institutes, H1 2019  
Products under Investigation by Universities/Institutes, H1 2019  
Number of Products by Stage and Mechanism of Actions, H1 2019  
Number of Products by Stage and Route of Administration, H1 2019  
Number of Products by Stage and Molecule Type, H1 2019  
Pipeline by AlfaSigma SpA, H1 2019  
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019  
Pipeline by Genentech Inc, H1 2019  
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019  
Pipeline by IMPACT Therapeutics Inc, H1 2019  
Pipeline by Mayne Pharma Group Ltd, H1 2019  
Pipeline by PellePharm Inc, H1 2019  
Pipeline by Pfizer Inc, H1 2019  
Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2019  
Dormant Products, H1 2019  
Discontinued Products, H1 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

### COMPANIES MENTIONED

AlfaSigma SpA

F. Hoffmann-La Roche Ltd

Genentech Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

IMPACT Therapeutics Inc

Mayne Pharma Group Ltd

PellePharm Inc

Pfizer Inc

Sun Pharma Advanced Research Company Ltd

## I would like to order

Product name: Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2019

Product link: <https://marketpublishers.com/r/S5A0AD0F600EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S5A0AD0F600EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970